4 March 2024
ValiRx PLC ("ValiRx" or the
"Company")
Proposed Appointment of Non-Executive
Director
London, UK - ValiRx Plc (AIM: VAL), a life
science company focusing on early-stage cancer therapeutics and
women's health is pleased to announce that, subject to normal
regulatory due diligence, it intends to appoint Luke Cairns as an
Independent Non-Executive Director of the Company.
Luke is an experienced corporate
finance professional with over 20 years of working with SMEs as
both an adviser and director. He was previously Head of Corporate
Finance and Joint Managing Director at Northland Capital Partners
Limited, an AIM Nominated Adviser and broker firm, and has worked
with many companies across several sectors and regions on a wide
range of transactions, including IPOs, secondary fundraisings,
corporate restructurings and takeovers.
Subsequently, Luke set up his own
consultancy working with growth companies and family offices and
now sits on number of private and public boards.
Dr Kevin Cox,
Chair of ValiRx PLC, commented "Luke will
be an excellent addition to the Board of ValiRx given his extensive
experience in small companies, corporate finance and corporate
governance. He will provide help and advice across all areas of the
business but particularly in respect of ValiRx as a quoted company.
His independent and objective views will help ensure continued
progress of our strategic plans."
Dr Suzy Dilly,
CEO of ValiRx PLC commented "I'm looking
forward to working with Luke, drawing on his public market
experience and in doing so enabling me to focus on driving the
business forward in line with all our shareholders
ambitions."
The information contained within this
announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of
the Company take responsibility for this announcement.
For more information, please
contact:
ValiRx
plc
Dr Suzanne Dilly, CEO
|
Tel: +44 (0)
2476 796496
www.valirx.com
Suzanne.Dilly@valirx.com
|
V Formation
(Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
|
+44 (0) 115
787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
Cairn
Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Ludovico
Lazzaretti
|
Tel: +44 (0)
20 7213 0880
|
Shard Capital
Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0)
20 7186 9000
|
Notes for
Editors
About
ValiRx
ValiRx is a life science company focused on
early-stage cancer therapeutics and women's health, accelerating
the translation of innovative science into impactful medicines to
improve patient lives.
ValiRx provides the scientific, financial, and
commercial framework for enabling rapid translation of innovative
science into clinical development.
Using its extensive and proven experience in
research and drug development, the team at ValiRx selects and
incubates promising novel drug candidates and guides them through
an optimised process of development, from pre-clinical studies to
clinic and investor-ready assets.
ValiRx connects diverse disciplines across
scientific, technical, and commercial domains, with the aim of
achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's portfolio are
outlicensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of the London
Stock Exchange in October 2006 and trades under the ticker symbol:
VAL.
For further information, visit:
www.valirx.com
Cautionary
statement
Certain statements made in this announcement
are forward-looking statements. Such statements are based on
current expectations and assumptions and are subject to a number of
risks and uncertainties that could cause actual events or results
to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons
receiving this announcement should not place undue reliance on
forward-looking statements. Unless otherwise required by applicable
law, regulation or accounting standard, the Company does not
undertake to update or revise any forward-looking statements,
whether as a result of new information, future developments or
otherwise.